Lithium gluconate 8% vs. ketoconazole 2% in the treatment of seborrhoeic dermatitis: A multicentre, randomized study

British Journal of Dermatology

Volumn 148, Issue 6, 2003, Pages 1230-1236

  Dreno, Brigitte ^a   Chosidow, O ^b   Revuz, J ^c   Moyse, D ^d  

^a CLINIQUE DERMATOLOGIQUE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d NONE

Author keywords

Lithium; Randomized controlled trial; Seborrhoeic dermatitis; Trace element

Indexed keywords

KETOCONAZOLE; LITHIUM GLUCONATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; EMULSION; ERYTHEMA; FACE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OINTMENT; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN BURNING SENSATION; SKIN EXFOLIATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; DERMATITIS, SEBORRHEIC; DERMATOLOGIC AGENTS; FEMALE; GLUCONATES; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0038346439     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05328.x     Document Type: Article

References (14)

1. Green CA, Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole: response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol 1987; 116: 217-21.
2. Ford GP, Farr PM, Ive FA, Shuster S. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984; 111: 603-7.
3. Pierard GE, Pierard-Franchimont C. Cutsem J et al. Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. Int J Dermatol 1991; 30: 806-9.
4. Christodoulou G, Georgala S, Vareltzides A, Catsarou A. Lithium in seborrheic dermatitis. Psychiatr J Univ Ott 1983; 8: 27-9.
5. Boyle J, Burton JL, Faergemann J. Use of topical lithium succinate for seborrhoeic dermatitis. Br Med J 1986; 292: 28.
6. Efalith Multicenter Trial Group. A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 1992; 26: 452-7.
7. Cuelenaere C, De Bersaques J, Kint A. Use of topical lithium succinate in the treatment of seborrhoeic dermatitis. Dermatology 1992; 184: 194-7.
8. Langtry JAA. Rowland Payne CME, Staughton RDC et al. Topical lithium succinate ointment (Efalith) in the treatment of AIDS-related seborrhoeic dermatitis. Clin Exp Dermatol 1997; 22: 216-9.
9. EMEA Committee for Proprietary Medicinal Products (CPMP) Efficacy Working Party (EWP). Points to consider on switching between superiority and non-inferiority. CPMP/EWP/482/99 (July 2000).
10. Dupuy P, Maurette C, Amoric JC, Chosidow O and the Study Investigator Group. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol 2001; 144: 1033-7.
11. Leeming JP, Burton JL. Lithium succinate and seborrhoeic dermatitis: an antifungal mode of action? Br J Dermatol 1990; 122: 718-9.
12. Nenoff P, Haustein UF. Munzberger C. In vitro activity of lithium succinate against Malassezia furfur. Dermatology 1995; 190: 48-50.
13. Horrobin DF. Lithium, fatty acids and seborrhoeic dermatitis: a new mechanism of lithium action and a new treatment for seborrhoeic dermatitis. Lithium 1990; 1: 149-55.
14. Horrobin DF. Effects of lithium on essential fatty acid and prostaglandin metabolism. In: Lithium and Cell Physiology. New York: Springer-Verlag. 1990: 137-49.